Alkmena Kafazi

Dr. Alkmena Kafazi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Journal of Critical Care Medicine
Verified
Journal Article
Open access
PDF file
AKAlkmena Kafazi
Alkmena Kafazi
EAEleni Apostolopoulou
Eleni Apostolopoulou
VBVasiliki Benetou
Vasiliki Benetou
GKGeorgia Kourlaba
Georgia Kourlaba
CSChristos Stylianou
Christos Stylianou
IPIoanna D Pavlopoulou
Ioanna D Pavlopoulou
Introduction: Cost analysis is complicated by the fact that patients acquire infections during their hospital stay, having already spent time at risk without having an infection. Multi-state models (MSM) accounts for this time at risk treating infections as time-dependent exposures from ICU admission. Aim of the study: To estimate ventilator-associated events (VAEs) direct additional cost in ICU patients. Material and Methods: This was a prospective, observational study carried out for a two-year period in four medical-surgical ICUs of Athens, Greece. The sample consisted of adult patients who received mechanical ventilation for ≥4 days and were followed until discharge from the ICU or until death. CDC standard definitions were used to diagnose VAEs. To estimate VAEs additional length of stay (LOS), we used a four-state model that accounted for the time of VAEs. The direct hospital cost was calculated, consisting of the fixed and variable cost. The direct additional cost per VAEs episode was calculated by multiplying VAEs extra LOS by cost per day of ICU hospitalization. Results: In the final analysis were included 378 patients with 9,369 patient-days. The majority of patients were male (58.7%) with a median age of 60 years. Of 378 patients 143 (37.8%) developed 143 episodes of VAEs. VAEs crude additional LOS was 17 days, while VAE mean additional LOS after applying MSM was 6.55±1.78 days. The direct cost per day of ICU hospitalization was € 492.80. The direct additional cost per VAEs episode was € 3,227.84, € 885.56 the fixed and € 2,342.28 the variable cost. Antibiotic cost was € 1,570.95 per VAEs episode. The total direct additional cost for the two-year period was € 461,581.12. Conclusions: These results confirm the importance of estimating VAEs real cost using micro-costing for analytical cost allocation, and MSM to avoid additional LOS and cost overestimation.

Verified
Journal Article
Open access
PDF file
AKAlkmena Kafazi
Alkmena Kafazi
EAEleni Apostolopoulou
Eleni Apostolopoulou
EAEvmorfia Andreou
Evmorfia Andreou
AGAlexandra Charalambos Gavala
Alexandra Charalambos Gavala
ESEvagelos Stefanidis
Evagelos Stefanidis
PMPavlos M Myrianthefs
Pavlos M Myrianthefs
Device-associated infections (DAIs) are a significant public health concern because of their attributable mortality, along with the extra length of stay and cost. This two- year prospective surveillance study aimed to assess the incidence of DAIs and their clinical impact on four Greek adult medical-surgical Intensive Care Units (ICUs). Centers for Disease Control and Prevention (CDC) definitions were used to diagnose DAIs. Of the 500 patients hospitalized for 12,624 days, 254 (50.8%) experienced 346 episodes of DAIs. The incidence of DAIs was 27.4 episodes per 1000 bed-days. The incidence of ventilator-associated events (VAEs), central line-associated bloodstream infections (CLABSIs), and catheter-associated urinary tract infections (CAUTIs) was 20.5 episodes per 1000 ventilator-days, 8.6 episodes per 1000 central line-days, and 2.5 episodes per 1000 catheter-days, respectively. The most common pathogens isolated were Acinetobacter baumannii (35.7%) and Klebsiella pneumoniae (29.9%). All gram-negative pathogens were carbapenem-resistant. The ICU’s mortality was 44.9% for patients with DAIs and 24.8% for patients without a DAI (attributable mortality 20.1%, p < 0.001), while the mean ICU length of stay was 34.5 days for patients with DAIs and 15.6 days for patients without a DAI (attributable length of stay 18.9 days, p < 0.001). The high incidence of multidrug-resistant pathogens and the attributable length of stay and mortality of DAIs emphasize the need to establish an organized antimicrobial surveillance program and implement a care bundle for DAI prevention in ICUs with personnel educational training, monitoring, and feedback.

6 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AKAlkmena Kafazi
Alkmena Kafazi
EAEleni Apostolopoulou
Eleni Apostolopoulou
EAEvmorfia Andreou
Evmorfia Andreou
AGAlexandra Charalambos Gavala
Alexandra Charalambos Gavala
ESEvagelos Stefanidis
Evagelos Stefanidis
PMPavlos M Myrianthefs
Pavlos M Myrianthefs
Device-associated infections (DAIs) are a significant public health concern because of their attributable mortality, along with extra length of stay and cost. This two- year prospective, surveillance study aimed to assess the incidence of DAIs and their clinical impact on 4 Greek adult medical-surgical ICUs. Centers for Disease Control and Prevention (CDC) definitions were used to diagnose DAIs. Of the 500 patients hospitalized for 12,624 days, 254 (50.8%) experienced 346 episodes of DAIs. The incidence of DAIs was 27.4/1,000 bed-days. The incidence of ventilator-associated events (VAEs), central line-associated bloodstream infections (CLABSIs), and catheter-associated urinary tract infections (CAUTIs) was 20.5/1,000 ventilator-days, 8.6/1,000 central-line days and 2.5/1,000 catheter-days, respectively. The most common pathogen isolated was Acinetobacter baumannii (35.7%%) and Klebsiella pneumoniae (29.9%). All gram-negative pathogens were carbapenem-resistant. DAIs attributable mortality was 20.1% (p = 0.000), while attributable length of stay was 18.9 days (p = 0.000), respectively. The high incidence and attributable length of stay and mortality of DAIs emphasize the need to establish an organized infection surveillance program and implement a care bundle for DAIs prevention in ICUs.